dolutegravir + lamivudine + tenofovir disoproxil fumarate

Dolutegravir + lamivudine + tenofovir disoproxil fumarate is a fixed-dose combination (FDC) antiretroviral therapy manufactured by Quality Chemicals Industries Limited (QCIL) for the treatment of HIV-1 infection. This combination, commonly referred to as TLD, is recognized by the World Health Organization (WHO) as a preferred first-line regimen for adults and adolescents. It consists of dolutegravir, an integrase strand transfer inhibitor (INSTI), lamivudine, a nucleoside reverse transcriptase inhibitor (NRTI), and tenofovir disoproxil fumarate, a nucleotide reverse transcriptase inhibitor (NtRTI). The medication works by simultaneously blocking the viral integrase enzyme, which prevents the integration of HIV DNA into the host cell genome, and the reverse transcriptase enzyme, which halts the synthesis of viral DNA. This dual-mechanism approach effectively suppresses viral replication and is administered as a single daily oral tablet.

Other names

Dolutegravir/Lamivudine/Tenofovir 50/300/300mg